Australia’s Neuren Pharmaceuticals has announced top-line results from its Phase II trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). 28 May 2024
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) along 28 May 2024
Oncology-focused biotech company Tango Therapeutics is to discontinue development of its TNG348 program due toxicity observed in the initial study cohorts. 24 May 2024
Californian company Cytokinetics closed Thursday’s trading down 17% after announcing a couple of updates that will add $1 billion to its cash pile. 24 May 2024
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief m 23 May 2024
Roche’s Japan-based subsidiary Chugai has launched PiaSky for injection 340 mg (crovalimab), a pH-dependent binding humanized anti-complement (C5) monoclonal an 23 May 2024
Cell engineering company MaxCyte (Nasdaq: MXCT) has entered into a strategic platform license agreement with Legend Biotech, another company focused on cell the 23 May 2024
SpyBiotech, a biotechnology company specializing in innovative vaccine platforms, has entered into a research agreement with the University of Oxford. 23 May 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.